Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Discovery
Akero debuts with $65 million to tackle NASH
by Lisa M. Jarvis
June 30, 2018
| A version of this story appeared in
Volume 96, Issue 27
Akero Therapeutics has launched with $65 million in its first formal round of financing to tackle nonalcoholic steatohepatitis, a disease marked by accumulation of fat and scarring on the liver. The cash will support the clinical development of ARK-001, a long-acting fibroblast growth factor 21 analog licensed from Amgen. Akero is the latest in a crop of well-funded biotech firms focused on NASH, for which there is no treatment, despite affecting an estimated 16 million Americans.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter